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Mental HealtH
Living well for longer
Pharmacy Guidance on Smoking  
and Mental Disorder  
Key learninG PointS »  Smoking is the single largest cause of 
preventable death in the UK and a major 
determinant of health inequality for those  
with a mental disorder.
»  With appropriate support, those with a mental 
disorder are able to stop smoking.
»  Doses of some psychiatric medication require 
significant reduction following smoking cessation.
»  A range of pharmacological interventions (such 
as combination nicotine replacement therapy 
or varenicline) and non-pharmacological 
interventions are effective in supporting smoking 
cessation for people with a mental disorder.
»  Pharmacists have a key role in improving 
access to smoking cessation and reduction 
interventions for smokers with a mental 
disorder as well as facilitating appropriate 
changes of medication doses. 
Smoking – the  
biggest killer
Smoking is associated with an increased 
risk of several chronic diseases 1 and is 
the single largest cause of preventable 
death with smokers dying on average 
10 years earlier than non-smokers 2. 
In 2014, there were 78,000 deaths 
attributable to smoking in England 3. 
Smoking and  
mental disorder 
People with different mental disorders 
have a 10-20 year lower life expectancy 1 
with smoking recognised as the single 
largest preventable cause. Since 42%  
of adult tobacco consumption in 
England is by those with a mental 
disorder 4, this group experiences a 
significant proportion of overall tobacco 
related harm. Furthermore, the annual 
health service cost of smoking by those 
with a mental disorder in the UK was 
£719m in 2009/10 5.
Smoking cessation  
and reduction in those  
with a mental disorder 
Smoking cessation results in improved physical 
and mental health 1. Furthermore, evidence 
suggests that the impact of smoking cessation 
on anxiety and depressive symptoms is at 
least as large as antidepressants 6. Smoking 
cessation is the single largest way to 
reduce the 10-20 year premature mortality 
experienced by those with a mental disorder. 
Pharmacotherapy and non-pharmacological 
support are effective in supporting 
smoking cessation in those with a mental 
disorder 1. Furthermore, interventions can 
also support people who are not ready 
to stop smoking completely by helping 
them to reduce the amount they smoke. 
Over time this can help to double smoking 
cessation rates 7.
Despite being as motivated to stop as the 
general population, those with a mental 
disorder are less likely to receive smoking 
cessation interventions. Taking action 
to support those with a mental disorder 
to quit smoking should be even more 
imperative, given the rates of comorbid 
physical health problems and reduced life 
expectancy within this population.
Medication dose reduction 
following smoking cessation 
Smoking increases the metabolism of different 
medications, including some antidepressants 
(tricyclics and mirtazapine), antipsychotics 
(clozapine, olanzapine and haloperidol) 8, 9, some 
benzodiazepines and opiates 10. This can result in 
significantly lower plasma levels 11 and therefore, 
larger doses are required for a similar therapeutic 
effect. Stopping smoking can reduce metabolism 
of some medication resulting in higher, sometimes 
toxic plasma levels over a few days 11, 12. Therefore, 
close monitoring is required and doses of the 
medications above need to be reduced within 
days of cessation and by up to 50% within a 
month of cessation. It is recommended that 12:
•	 Plasma	levels	of	clozapine	(and	olanzapine	
if assays are available) should be measured 
before smoking cessation to enable 
more accurate and timely monitoring 
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and adjustment of medications. Doses of 
clozapine and olanzapine should be reduced 
by 25% during the first week of cessation 
and then further plasma levels taken on  
a weekly basis until levels have stabilised 
•	 Doses	of	fluphenazine	and	some	
benzodiazepines should be reduced by  
up to 25% in the first week of cessation 
•	 Tricyclic	antidepressants	may	need	to	be	
reduced by 10-25% in the first week
•	 Further	dose	reductions	may	be	required	
with continued cessation 
Dose reduction of psychotropic medication 
following smoking cessation in those with 
a mental disorder in the UK would result in 
associated annual NHS savings of £40m 5. 
Medication dose reduction 
following smoking reduction 
Smoking reduction decreases the associated 
harm and increases the chances of stopping 
smoking among smokers in the general 
population 13. Smoking reduction can also 
decrease the metabolism of some medication. 
However, there is an important research gap 
regarding required dose changes for people 
who reduce their smoking but do not stop 
completely. In such cases, monitoring which 
includes regular blood tests for drug levels 
should inform such changes. 
Role of pharmacists
Pharmacists are highly accessible to different 
groups of the local population and are in an 
ideal position to:
•	 Explain	how	smoking	cessation	can	improve	
mental health as well as physical health 
•	 Encourage	people	to	stop	smoking	through	
promoting healthy lifestyles which is part  
of the pharmacy contractual framework
•	 Check	drug	interactions	between	medicines	
prescribed and/or taken as supplements 
•	 Highlight	to	patients	and	prescribers	the	
need for planned reduction of doses of 
some medications upon smoking cessation 
(as outlined above)
•	 Encourage	the	use	of	combined	NRT	to	 
all including those who continue to smoke 
which supports smoking reduction as a  
first step to cessation 
•	 Supply	smoking	cessation	pharmacotherapy	
through Patient Group Directions (PGDs)  
or as part of a local Enhanced Service 
•	 Coordinate	pharmacy	support	with	
community and inpatient mental health 
services, primary care providers and local 
Stop Smoking Services to offer ongoing 
smoking cessation support as part of a  
more integrated service
Pharmacy staff who are trained to provide 
advice on stopping smoking are likely to 
improve the support pharmacies can offer  
to people who wish to stop.
Smoking cessation and 
reduction pharmacotherapy 
Several different types of smoking cessation 
pharmacotherapy exist. When comparing 
different types of pharmacotherapy for the 
general population, be aware that 15, 16: 
•	 Different	types	of	NRT	are	similarly	effective	
for smoking cessation with nasal spray 
being slightly more effective followed by 
tablets /lozenges, inhalers, patches and  
gum which is slightly less effective 
•	 NRT	and	bupropion	are	equally	effective
•	 Varenicline	is	more	effective	than	bupropion	
or	single	forms	of	NRT
•	 Varenicline	is	as	effective	as	combined	NRT
•	 Addition	of	bupropion	or	nortriptyline	does	
not	increase	effectiveness	of	NRT
A	combination	of	different	forms	of	NRT	and	
NRT/bupropion	reduces	smoking	consumption	
in people with a mental disorder 5, 13, 14.
Nicotine replacement  
therapy (NRT)
NRT	is	effective	(OR	1.84,	1.71-1.99)	15.  
Several	different	forms	of	NRT	can	be	
prescribed 16, 17. The choice of which form  
to	use	should	reflect	patient	needs,	tolerability	
and cost considerations. Patches are likely  
to be easier to use than gum, nasal spray  
or inhaler although patches cannot be used 
for relief of acute cravings 16. The use of local 
Enhanced Services can also be considered in 
order to improve access: 
•	 Patches:	16-hour	and	24-hour	patches	 
are available with no difference in efficacy.  
Both types come in several strengths to 
allow	gradual	weaning.	A	high	dose	patch	
should be used for those who normally 
smoke more than 20 cigarettes per day
•	 Gum:	2mg,	4mg	or	6mg,	up	to	15	pieces	
daily can be  chewed at regular intervals
•	 Sublingual	tablets:	one	(2mg)	tablet	per	
hour for those smoking 20 cigarettes  
daily and two tablets per hour for those 
smoking 40 cigarettes daily
•	 Oral	film:	2.5mg	dissolved	in	the	mouth	 
up to 15 times a day
•	 Nasal	spray:	(500mcg)	maximum	dose	 
2 sprays per nostril per hour for up to  
16 hours per day
•	 Oral	spray:	1	or	2	sprays	of	1mg,	up	to	 
4 sprays per hour to a maximum of 64 
sprays a day
•	 Inhalator:	mouthpiece.	The	initial	dose	
should be up to twelve 10mg cartridges,  
or six 15mg cartridges per day
•	 Lozenges:	1mg,	1.5mg,	2mg	and	4	mg	 
up to maximum 15 per day
Combining	a	nicotine	patch	with	a	rapid-
delivery	form	of	NRT	is	more	effective	than	
a single type of nicotine replacement 15, 16 
particularly for more dependent smokers 
including those with a mental disorder who 
may need longer than the recommended 
8-12 weeks treatment 5, 14. Only cigarette 
smoking induces hepatic enzymes to alter 
drug plasma levels in the ways described 
above;	NRT	has	no	effect	on	enzyme	activity	
and therefore drug doses are not affected 
although require accompanying dose 
reductions of medications outlined above 
upon smoking cessation.
Side effects 15, 17
•	 Patches:	Skin	sensitivity	and	irritation
•	 Gum:	Hiccoughs,	gastrointestinal	problems,	
jaw pain and orodental problems
•	 Sublingual	tablets:	Hiccoughs,	burning,	 
sore throat, coughing and dry lips 
•	 Nasal	/oral	spray	and	inhalers:	Local	irritation	
•	 Serious	adverse	effects	are	absent	from	 
trial reports although there have been 
reports of possible increased risk of chest 
pain and heart problems 
E-cigarettes
Although	there	is	a	lack	of	evidence	about	
long term safety and more research is needed, 
e-cigarettes are widely considered to be 
much less harmful than cigarette smoking 18 
and used by 4% of adults in England 3. The 
main reasons for e-cigarette use are to aid 
stop smoking (53%) and being less harmful 
than cigarettes 3.	As	for	other	forms	of	NRT,	
e-cigarettes do not induce enzymes and so 
require accompanying dose reductions of 
medications outlined above if completely 
replacing tobacco smoking. 
Bupropion
Bupropion is an atypical antidepressant which acts 
as an adrenaline and dopamine reuptake inhibitor 
as well as nicotinic antagonist thereby reducing 
nicotine cravings and withdrawal symptoms. 
Bupropion is effective in the general population 
for	smoking	cessation	(OR	1.82,	1.60-2.06)	
with	a	combination	of	NRT	and	bupropion	
more effective than bupropion alone 15. For 
people with schizophrenia, bupropion almost 
triples cessation rates at six months 19. 
Dosing: start 1-2 weeks before planned quit 
date at 150mg daily for 6 days, then 150mg 
twice daily for maximum 7-9 weeks.
Side effects 
•	 Dry	mouth	(10%),	constipation,	nausea,	
insomnia (30-40%) and allergic reactions 15
•	 Serious	adverse	effects	(SAEs)	
 »  Seizures: Seizure rate (0.1%) was low 
although a report found it was much 
higher in accidental and intentional 
overdoses	(6%).	Rates	were	lower	for	
sustained-release formulations 
 »  Spontaneous abortion 
	 »	 	MHRA	described	reports	of	bupropion	
being associated with the development 
of depression, suicidal thoughts and 
behaviours, hallucinations, delusions, 
disordered thoughts and extreme mood 
swings. These effects were more likely 
in people who have had mental health 
problems before 20 
	 »	 	In	2009,	the	FDA	required	bupropion	
to carry the agency’s strongest safety 
warning due to side effects including 
changes in behaviour, hostility, agitation, 
depressed mood, suicidal thoughts 
and behaviour, and attempted suicide 
including in those with no previous 
history of psychiatric illness 21
 »  However, a meta-analysis of six trials found 
no	difference	in	neuropsychiatric	SAEs	
between bupropion and placebo 15.	A	further	
large prospective study found no increased 
risk of depression or suicidal behaviour 22
	 »	 	A	meta-analysis	of	bupropion	for	people	
with schizophrenia found no reported 
serious adverse events 19.	A	more	recent	
trial involving more than 4,000 people 
with a history of psychiatric disorder 
found that bupropion did not significantly 
increase the risk of neuropsychiatric 
adverse events 23
Contraindications
Bupropion is contraindicated for people with 
bipolar disorder and epilepsy. It should not 
be prescribed to people who have recently 
stopped taking sedatives or medicines to  
treat anxiety, eating disorder or who are  
heavy drinkers 20. 
Interactions
Bupropion should not be prescribed 
with other drugs which increase risk of 
seizure such as tricyclic antidepressants, 
monoamine	oxidase	inhibitors	(MAOIs)	and	
some antipsychotic medication including 
clozapine, chlorpromazine and depot 
injections 12. Bupropion can increase blood 
levels of citalopram so should not be taken 
concurrently and should be avoided for two 
weeks after stopping 17. However, the two 
drugs have been used safely as co-therapy 24. 
Varenicline
Varenicline	(OR	2.88,	2.40-3.47)	is	a	nicotine	
receptor partial agonist and as effective as 
combination	NRT	although	more	effective	 
than	either	single	form	NRT	or	bupropion	15. 
Dosing: Usually started 1-2 weeks before 
target stop date at 500mcg daily for 3 days, 
then 500mcg twice daily for 4 days and then 
increased to 1mg twice daily for a further  
11 weeks.
Side effects 
•	 Main	side	effect	is	nausea	while	other	
common side effects include insomnia, 
abnormal dreams and headaches 15
•	 Serious	adverse	effects	(SAEs)	
	 »	 	A	meta-analysis	found	no	increased	rate	
of	any	SAE	or	neuropsychiatric	SAE	in	
people taking varenicline compared to 
placebo 15.	A	further	large	prospective	
study found no increased risk of 
depression or suicidal behaviour 22.	A	
more recent trial involving more than 
4,000 people with a history of psychiatric 
disorder found that varenicline did 
not significantly increase the risk of 
neuropsychiatric adverse events 23
	 »	 	In	2009,	the	FDA	required	varenicline	
to carry the agency’s strongest safety 
warning due to side effects including 
changes in behaviour, hostility, agitation, 
depressed mood, suicidal thoughts 
and behaviour, and attempted suicide 
including in those with no previous history 
of psychiatric illness 21. However, the 
EMA	has	recently	removed	the	black	box	
warning 25 following further evaluation 
outlined above
	 »	 	Changes	in	behaviour	or	thinking,	
anxiety, psychosis, mood swings, 
aggressive behaviour, depression, suicidal 
ideation and behaviour and suicide 
attempts have been reported in patients 
taking varenicline in post-marketing 
surveillance 25 
Need for close monitoring 
while taking bupropion  
and varenicline
•	 If	patients	taking	varenicline	or	bupropion	
develop suicidal thoughts, agitation, 
depressed mood, or display any changes 
in behaviour which are of concern for the 
doctor, pharmacist, patient, family, or carer, 
they should stop bupropion or varenicline 
and contact their doctor immediately 20, 25
•	 Care	should	be	taken	with	patients	with	
a history of psychiatric illness and patients 
should be advised accordingly 25 
•	 Close,	regular	monitoring	by	health	
professionals including psychiatrists, GPs 
and community health staff should occur 
through a clearly negotiated plan of support 
and contact especially in the first 2-3 weeks 
with clear strategies for responding in the 
event of changes
•	 If	varenicline	or	bupropion	is	stopped	due	 
to neuropsychiatric symptoms, patients 
should be monitored closely until the 
symptoms resolve
•	 Family	members	and	carers	should	also	be	
alerted to the potential for such changes 
and be an active part of any negotiated 
support plan, with the person’s consent
Nortriptyline and cytisine
Evidence also highlights the effectiveness of 
nortriptyline	(OR	2.03,	1.48-2.78)	and	cytisine	
(OR	3.98,	2.01-7.87)	without	significant	
adverse effects 15. However, these treatments 
are unlicensed in the UK.
Level of smoking cessation 
pharmacotherapy provision 
and associated expenditure 
Over the last ten years in England, the number 
of smoking cessation prescription items 
dispensed has reduced from 2 million to 1.3 
million 3. This has been primarily due to a 
reduction	of	NRT	items	dispensed	from	2.1	
million to 0.8 million. There has been a similar 
42% reduction in net ingredient cost from 
£65.9 million in 2010/11 to £38.1 million in 
2014/15 (3). In contrast, there are 2.2 million 
current users of e-cigarettes. n 
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